CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S154
DOI: 10.1055/s-0038-1640243
Abstracts
Otologie: Otology
Georg Thieme Verlag KG Stuttgart · New York

Otolin-1 in Biological Fluids: A Possible Biomarker for Inner Ear Disease

E Avallone
1  HNO-Klinik der Medizinische Hochschule Hannover, Hannover
,
H Schmitt
2  Hearing4All Cluster of Excellence DFG, Hannover
,
G Lilli
1  HNO-Klinik der Medizinische Hochschule Hannover, Hannover
,
A Warnecke
3  HNO-Klinik der Medizinische Hochschule Hannover – Hearing4All Cluster of Excelle, Hannover
,
A Lesinski-Schiedat
1  HNO-Klinik der Medizinische Hochschule Hannover, Hannover
,
T Lenarz
3  HNO-Klinik der Medizinische Hochschule Hannover – Hearing4All Cluster of Excelle, Hannover
,
K Willenborg
1  HNO-Klinik der Medizinische Hochschule Hannover, Hannover
› Author Affiliations
DFG Exzellenzcluster Hearing4All (EXC 1077/1)
Further Information

Publication History

Publication Date:
18 April 2018 (online)

 

Objective:

The expression of Otolin-1 mRNA is highly restricted to the inner ear. A previous study showed that Otolin-1 is present in a significantly higher level in serum samples of patients with benign paroxysmal positional vertigo compared to healthy patients. Menière's disease (M.d.) leads to changes in the inner ear volumes and pressure. We therefore hypothesize that significantly increased levels of the protein Otolin-1 can be detected in blood, urine or saliva of patients suffering from M.d.

Material and Methods:

10 patients with acute M.d. were included in the present study. The control group consists of 10 subjects without any history of otoneurological disease. The sampling was performed in the morning after at least 12 hours of fasting. Detection of Otolin-1 concentration was performed by the use of a highly sensitive ELISA-kit for human Otolin-1.

Results:

Otolin-1 was detected in pg/ml range in all collected samples. The highest values were detected in saliva whereas the lowest ones were detected in urine. Serum samples of 9 out of 10 patients suffering from M.d. showed significantly higher Otolin-1 values than control samples (n = 10; p < 0.001). There was no significant difference in the saliva or urine concentrations of Otolin-1 between patients of the M.d. and of the control group.

Conclusion:

Our results indicate that Otolin-1 is present in serum and also in saliva, but rarely in urine of patients with the M.d. and controls. The highly significant difference in serum samples of M.d. patients and controls seems indicative for a biomarker function of Otolin-1 in the acute state of the M.d. However, high levels can also be found in patients with BPPV or increased age.